Method for reducing central nervous system tissue or cell damage in a subject due to stroke
View Patent ↗Peptides able to inhibit or activate the translocation or function of δPKC are identified. Administration of the peptides for protection or enhancement of cell damage due to ischemia is described. Therapeutic methods to reduce damage to cells or to enhance damage to cells due to ischemia are also described, as well as methods for screening test compounds for δPKC-selective agonists and antagonists.
1. A method for reducing central nervous system tissue or cell damage in a human subject due to ischemic stroke, comprising
administering to said subject a conjugate comprising (a) a peptide comprising the amino acid sequence of SEQ ID NO: 4, and (b) a transport moiety effective to facilitate transport across a cell membrane, wherein said peptide and transport moiety are linked, and wherein said administering is effective to reduce central nervous system tissue or cell damage due to ischemic stroke.
2. The method of claim 1 , wherein said peptide consists of the amino acid sequence of SEQ ID NO:4.
3. A method for reducing central nervous system tissue or cell damage in a human subject due to ischemic stroke, comprising
administering to said subject a conjugate comprising (a) a first peptide comprising the amino acid sequence of SEQ ID NO: 4, and (b) a second peptide comprising the amino acid sequence of SEQ ID NO: 9, wherein said first and second peptides are cross-linked via a disulfide bond, and wherein said administering is effective to reduce central nervous system tissue or cell damage due to ischemic stroke.
4. The method of claim 3 , wherein said first peptide consists of the amino acid sequence of SEQ ID NO:4 and a terminal cysteine.
5. A method for reducing central nervous system tissue or cell damage in a human subject due to ischemic stroke, comprising
administering to said subject a conjugate comprising (a) a first peptide consisting of the amino acid sequence of SEQ ID NO: 4 and a first terminal cysteine, and (b) a second peptide consisting of the amino acid sequence of SEQ ID NO: 9 and a second terminal cysteine, wherein the first and second peptides are cross-linked via a disulfide bond between the first and second terminal cysteine, and wherein said administering is effective to reduce central nervous system tissue or cell damage due to ischemic stroke.
6. A method for reducing central nervous system tissue or cell damage in a human subject due to ischemic stroke, comprising
administering to said subject a composition comprising a conjugate and a carrier or encapsulant, wherein said conjugate comprises (a) a peptide comprising the amino acid sequence of SEQ ID NO: 4, and (b) a transport moiety effective to facilitate transport across a cell membrane, wherein said peptide and transport moiety are linked, and wherein said administering is effective to reduce central nervous system tissue or cell damage due to ischemic stroke.
7. The method of claim 6 , wherein said peptide consists of the amino acid sequence of SEQ ID NO:4.
8. A method for reducing central nervous system tissue or cell damage in a human subject due to ischemic stroke, comprising
administering to said subject a composition comprising a conjugate and a carrier or encapsulant, wherein said conjugate comprises (a) a first peptide comprising the amino acid sequence of SEQ ID NO: 4, and (b) a second peptide comprising the amino acid sequence of SEQ ID NO: 9, wherein the first and second peptides are cross-linked via a disulfide bond, and wherein said administering is effective to reduce central nervous system tissue or cell damage due to ischemic stroke.
9. The method of claim 8 wherein said first peptide consists of the amino acid sequence of SEQ ID NO:4 and a terminal cysteine.
10. A method for reducing central nervous system tissue or cell damage in a human subject due to ischemic stroke, comprising
administering to said subject a composition comprising a conjugate and a carrier or encapsulant, wherein said conjugate comprises (a) a first peptide consisting of the amino acid sequence of SEQ ID NO: 4 and a first terminal cysteine; and (b) a second peptide consisting of the amino acid sequence of SEQ ID NO: 9 and a second terminal cysteine, wherein the first and second peptides are cross-linked via a disulfide bond between the first and second terminal cysteine, and wherein said administering is effective to reduce central nervous system tissue or cell damage due to ischemic stroke.
11. The method of any one of claims 1 - 10 , wherein said administering comprises intravenously administering.
12. The method of any one of claims 1 - 10 , wherein said administering occurs prior to said stroke.
13. The method of any one of claims 1 - 10 , wherein said administering occurs during said stroke.
14. The method of any one of claims 1 - 10 , wherein said administering occurs after said stroke.